Gentian Diagnostics ASA (OSE:GENT), a manufacturer of in vitro diagnostic reagents, announced on Monday that it has partnered with Beckman Coulter Diagnostics to launch the GCAL Calprotectin Immunoassay on Beckman Coulter's clinical chemistry platforms.

This collaboration aims to improve diagnostic efficiency and support better treatment decisions.

The GCAL Calprotectin Immunoassay measures calprotectin levels in human plasma and serum, a key biomarker for detecting and assessing inflammation. It is applicable in a range of inflammatory and rheumatic diseases, as well as in infection-related risk assessments.

Gentian Diagnostics CEO Matti Heinonen said that this partnership strengthens the company's market presence and advances the adoption of circulating calprotectin testing. The collaboration leverages Beckman Coulter's expertise and distribution network to enhance diagnostic accuracy and patient care.